Get started
Work

Tackling Multiple Biologic Failure in Psoriasis: Research and Advocacy Perspectives

Year: 2024
Type: editorial
Abstract: Psoriasis is an immune-mediated skin disease commonly treated with biologic therapies. While there are currently 12 different biologics approved for psoriasis, there still exists a challenging subset of patients who have tried and failed biologics from multiple classes. In this commentary, we discuss the research and advocacy-based efforts by the National Psoriasis Foundation (NPF) and academic collaborators to understand and better support multiple biologic failure (MBF) psoriasis patients. The NPF MBF registry will gather clinical and demographic information on MBF patients to improve therapeutic outcomes, while legislative efforts through NPF Capitol Hill Day aim to advance federal laws in support of all psoriasis patients, with a recent focus on access to biologic therapy. Together, these 2 efforts will improve the care for all people living with psoriasis, including those experiencing MBF.
DOI: 10.1177/24755303241288536
Authors: Kathryn Haran, George Gondo, Payton Smith, Chandler Johnson, Allison Kranyak, Tina Bhutani, Wilson Liao
Language: English
Subfield: Immunology
Open Access status: hybrid
Estimated APC paid: $3,700
Funders: Amgen, Bristol-Myers Squibb, National Psoriasis Foundation, Eli Lilly and Company, Pfizer, Sanofi, AbbVie, Regeneron Pharmaceuticals, Castle Biosciences, Seconda Università degli Studi di Napoli, LEO Pharma, Janssen Biotech
OpenAlex ID: W4402981324
Cites: 4
Cited by: 1
Related to: 10